康龙化成 (300759)
Pharmaron Beijing Co., Ltd.
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 177819.55
- Circulating A-Shares(W): 141938.46
- Earnings Per Share(RMB): 0.6477
- Net Assets Per Share(RMB): 8.2179
- Operating Revenue(W RMB): 1008562.32
- Total Profit(W RMB): 132893.38
- Net Profit Attributable to Parent(W RMB): 114091.22
- Net Profit Growth Rate(%): -19.76
- Weighted Return on Equity(%): 8.0500
- Operating Cash Flow Per Share(RMB): 1.3700
- Undistributed Profit Per Share(RMB): 4.0665
- Capital Reserve Per Share(RMB): 2.7732
2. Main Business
The main business covers:
- Laboratory Services
- CMC (Small Molecule CDMO) Services
- Clinical Research Services
- Macromolecule and Cell & Gene Therapy Services
3. Company Basic Information
- Company Name: Pharmaron Beijing Co., Ltd.
- Listing Date: 2019-01-28
- Industry: Research and Experimental Development
- Address: No. 6 Taihe Road, Beijing Economic-Technological Development Area, Beijing, China
- Website: www.pharmaron.com
- Company Profile: On July 21, 2016, Pharmaron Limited held a board meeting and agreed to change the company into a joint stock company. All shareholders of Pharmaron Limited signed the "Sponsor Agreement" as sponsors. Based on the audited net assets of Pharmaron Limited as of February 29, 2016, amounting to RMB 938,500,686.29, the company was converted into 500,000,000 shares to establish the joint stock company. The portion of net assets exceeding the share capital was recorded as the issuer's capital reserve. On August 4, 2016, the Management Committee of Beijing Economic-Technological Development Area approved the change of Pharmaron (Beijing) New Drug Technology Co., Ltd. into a foreign-invested joint stock company with the approval document (Jing Ji Guan Xiang Shen Zi [2016] No. 175). On August 8, 2016, the Beijing Municipal Government reissued the "Foreign Investment Enterprise Approval Certificate" (Shang Wai Zi Jing Zi [2004] No. 17150) to the issuer. On August 9, 2016, ShineWing verified the company's registered capital and issued the "Capital Verification Report" (XYZH/2016BJA30207), confirming that the shareholders' contributions were in place. On October 25, 2016, the issuer held its inaugural meeting. On October 27, 2016, the Beijing Administration for Industry and Commerce issued the "Business License" (Unified Social Credit Code: 9111030276350109XG) to the issuer.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Shenzhen Xinzhong Kangcheng Investment Partnership (Limited Partnership) | General Legal Person | 22348.83 | 15.75 |
| 2 | PHARMARON HOLDINGS LIMITED | General Legal Person | 18049.65 | 12.72 |
| 3 | China Europe Healthcare Hybrid Securities Investment Fund Class A | Fund | 7235.62 | 5.10 |
| 4 | Hong Kong Securities Clearing Company Ltd. | Northbound Funds | 5315.60 | 3.75 |
| 5 | Ningbo Longtaikang Investment Management Co., Ltd. | General Legal Person | 4013.50 | 2.83 |
| 6 | Shenzhen Xinzhong Longcheng Investment Partnership (Limited Partnership) | General Legal Person | 2849.85 | 2.01 |
| 7 | Huabao China Securities Medical Care ETF | Fund | 2506.59 | 1.77 |
| 8 | Beihai Duotai Venture Capital Co., Ltd. | General Legal Person | 2195.70 | 1.55 |
| 9 | E Fund ChiNext ETF | Fund | 2015.01 | 1.42 |
| 10 | China Merchants China Securities Bio-pharmaceutical Index Fund (LOF) Class A | Fund | 1347.02 | 0.95 |
5. Concept Sectors
- H-Share
- Artificial Intelligence
- CXO Concept
- Innovative Drugs
- AI Healthcare
- Margin Trading & Securities Lending
- High-Performance Stocks
- Heavily Held by Funds
- Shareholder Reduction
- MSCI Mid Cap
- Overseas Business
- Non-Cyclical Stocks
- Zhongchuang 100
- ChiNext Index
- SZSE 300
- Private Enterprise 100
- SZSE Growth
- CSI 300
- ChiNext 50
- ChiNext 300
- CSI 200
- 300 Non-Cyclical
- ChiNext Large Cap
- ChiNext Healthcare
- STAR 50
- 300 ESG
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information